SARS-COV-2 Immunoassays

Advancing Diagnostics of Covid-19

Understanding if a patient has been recently or previously infected with SARS-CoV-2, how long antibodies stay in the body, and how an individual immune response reacted to the vaccine are important steps in the COVID-19 pandemic. Serology tests can provide this broader picture. Abbott is partnering with laboratories around the world in the COVID-19 crisis by quickly bringing assays for the specific detection of SARS-CoV-2 antibodies. These tests are produced in the volumes required to support the urgent needs of laboratories in their mission to support ongoing patient care.


Whitepaper_Preview_425x292.pngDiscover the importance of
SARS-CoV-2 antibody testing


Download the whitepaper

 

 

Learn more about our SARS-CoV-2 IgM and IgG assays by selecting the tabs below.

SARS-CoV-2 IgG II Quant
 

Quant_icon.jpg


BACKGROUND

Research is ongoing to establish the extent to which IgG antibodies to SARS-CoV-2, and in particular neutralizing antibodies, confer immunity to infection. The ability to longitudinally detect and quantitate antibodies which are associated with neutralization of the virus will become increasingly important as vaccines and therapeutics gain widespread use.1

A wide range of COVID-19 vaccines utilize strategies that generate antibody response to the spike protein and the RBD domain of the S1 subunit.2

Plasma from convalescent donors with neutralizing levels of specific IgG has shown some efficacy in limiting the consequences of COVID-19.3 Several studies have alluded to the potential of antibody testing, correlated to neutralizing antibody titers, as part of the evaluation of convalescent COVID plasma (CCP) to assess potency and efficacy of the product.4,5




INTENDED USE 6, 7

The SARS-CoV-2 IgG II Quant assay is a chemiluminescent microparticle immunoassay (CMIA) used for the qualitative and quantitative determination of IgG antibodies to SARS-CoV-2 in human serum and plasma on the Alinity and ARCHITECT i Systems. The SARS-CoV-2 IgG II Quant assay is to be used as an aid in the diagnosis of SARS-CoV-2 infection in conjunction with clinical presentation and other laboratory tests. 

The assay is also to be used as an aid in evaluating immune status of infected individuals and to monitor antibody response in individuals that have received the COVID-19 vaccine, by quantitatively measuring IgG antibodies against the spike receptor-binding domain (RBD) of SARS-CoV-2. Results from the SARS-CoV-2 IgG II Quant assay should not be used as the sole basis for diagnosis of SARS-CoV-2 infection.

 

 

Specific PERFORMANCe Characteristics 

Our highly sensitive and specific SARS-CoV-2 IgG II Quant assay (positive and negative percent agreement tables below) has demostrated the ability to detect the spike RBD-based vaccine response (Pfizer-BioNTech COVID-19 cohort represented in the chart below) in longitudinal samples from individuals both with and without prior COVID-19 infection.

POSITIVE AGREEMENT (POST SYMPTOM ONSET) 6
 
SARS-COV-2 IGG II QUANT ASSAY RESPONSE ACROSS TIME POINTS 6,7
SARS-CoV-2-IGG-II_Quant-Assay_PosAgrrnt-Neutralization_Charts_550x363.jpg

Negative AGREEMENt 6,7
IGG-II-Quant_Pos-Neg_Chart_550x123.jpg
SARS-CoV-2-IGG-II_Quant-Assay_Response-Time-Points_Chart_550x460.jpg
        
SARS-COV-2 IgM
 

Antibody-Graphic-igm_LCT.png


BACKGROUND

The presence of IgM antibodies allows for the identification of recent infection and evaluation of disease course. Accompanying an antibody test with an RNA test improves overall sensitivity of the viral diagnosis in the early stage of the infection.8





INTENDED USE 9,10

The SARS-CoV-2 IgM assay is a chemiluminescent microparticle immunoassay (CMIA) used for the qualitative detection of IgM antibodies to SARS-CoV-2 in human serum and plasma on the Alinity i and ARCHITECT i Systems.

The SARS-CoV-2 IgM assay is to be used as an aid in the diagnosis of SARS-CoV-2 infection in conjunction with clinical presentation and other laboratory tests. Results from the SARS-CoV-2 IgM assay should not be used as the sole basis for diagnosis.

 

CLINICAL PERFORMANCE 9,10

IgM_Clinical-Performance_1100x395.jpg           

The positive agreement between the ARCHITECT i2000sr and the Alinity i was 100.00% and the negative agreement was 99.97%. 

aTwenty-eight (28) specimens from 8 immunocompromised patient were excluded from the study. Refer to the LIMITATIONS OF THE PROCEDURE section of this package insert for further information. When the results from these specimens were included, the PPA at ≤ 7 days post-symptom onset was 45.26% (95% CI: 35.63, 55.26), the PPA at 8 - 14 days post-symptom onset was 79.56% (95% CI: 72.05, 85.46), the PPA at 15 - 30 days post-symptom onset was 91.26% (95% CI: 84.22, 95.33), and the PPA at ≥ 31 days post-symptom onset was 94.74% (95% CI: 75.36, 99.73). bDuration of the IgM antibody response has not been fully characterized.

SARS-Cov-2 IGG
 

Antibody-Graphic_LCT.png


BACKGROUND

The persistence of immunoglobulin class G (IgG) antibodies allows identification of people who have been infected in the past, recovered from the illness, and possibly developed immunity.3 Therefore, SARS-CoV-2 IgG immunoassays play an important role in research and surveillance.11





INTENDED USE 12,13

The SARS-CoV-2 IgG assay is a chemiluminescent microparticle immunoassay (CMIA) used for the qualitative detection of IgG antibodies to SARS-CoV-2 in human serum and plasma on the Alinity i and ARCHITECT i Systems.

The SARS-CoV-2 IgG assay is to be used as an aid in the diagnosis of SARS-CoV-2 infection in conjunction with clinical presentation and other laboratory tests. Results from the SARS-CoV-2 IgG assay should not be used as the sole basis for diagnosis.

 

CLINICAL PERFORMANCE 12,13           

IgG_Chart_clinical-performance_US.jpg

 The positive agreement between the ARCHITECT i2000SR and the Alinity i was 100% and the negative agreement was 99.00%.

a Five specimens from 1 immunocompromised patient were excluded from the study. Refer to the LIMITATIONS OF THE PROCEDURE section of the package insert for further information. When the results from these specimens were included, the PPA at ≥ 14 days post-symptom onset was 96.77% (95% CI: 90.86, 99.33).

 



Related Publications

More than 60,000 samples have been evaluated with Abbott’s SARS-CoV-2 assays in more than 60 publication/evaluations, seeking to provide key insights. Here are a few examples.

 

Check back frequently for more resources.

 

Publication Description
Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays in infected, recovered, and vaccinated groups Evaluation from University of Texas Southwestern Medical Center demonstrated a strong clinical performance of three distinct serological assays and their utility in evaluating and distinguishing serological responses to infection and vaccination.
Understanding COVID-19 Epidemiology and Implications for Control: The Experience from a Greek Semi-Closed Community Study highlighted the value of low-cost serosurveys targeting both symptomatic and asymptomatic populations to evaluate the natural immune response to SARS-CoV-2 in nonvaccinated susceptibles and design evidence-based policies for lifting lockdowns.
Anti-SARS-CoV-2 Antibodies Persist for up to 13 Months and Reduce Risk of Reinfection Team of researchers in Strasbourg, France, assessed the kinetics of SARS-CoV-2 antibodies and evaluated protection against reinfection and durability of vaccine protection.
Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests The Abbott Global Viral Surveillance program, in collaboration with researchers from Guy’s and St Thomas’ NHS Foundation, evaluated SARS-CoV-2 variants and their impact on diagnostic assay performance.
Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis Study from Tel Aviv University assessed humoral immune response and the factors associated with it in dialysis patient following vaccination.
Longitudinal characterization of the IgM and IgG humoral response in symptomatic COVID-19 patients using the Abbott Architect Researchers from Beaumont Health, Michigan, summarized that the combined use of IgM and IgG testing is useful to support a diagnosis of COVID-19 most notably in symptomatic individuals who test negative by molecular detection methods.
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study Study published in The Lancet showed how our SARS-CoV-2 IgG assay was recently involved in one of the largest (if not the largest) seroprevalence studies in Europe and it helped Spanish government determine what has happened and inform national and local public health policies. 
Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho Research from the University of Washington, published in the Journal of Clinical Microbiology, found our SARS-CoV-2 IgG assay had 99.9% specificity and 100% sensitivity for detecting the IgG antibody in people 17 days after symptoms began.

 

 
 

ALINITY IMMUNOASSAY SYSTEMS

Alinity is your total laboratory solution, a unified, holistic family of systems designed to deliver unprecedented integration across your laboratory. The SARS-CoV-2 assays are available on the Alinity i, a compact, immunoassay system that maximizes throughput and processes more tests per square meter than other systems, making it one of the most efficient on the market today. 

Alinity is transforming labs around the world with clinical chemistry, immunoassay and integrated systems. To discover more visit the Alinity ci-series page.

 

 
 

ARCHITECT IMMUNOASSAY SYSTEMS

Abbott's SARS-CoV-2 assays are also available on the high-throughput ARCHITECT i2000SR system, which can produce over 4,000 results in 24 hours, with a 29 minute time to first result. 

The ARCHITECT i2000SR and i1000SR meet your laboratory's high standards. For additional test menu, system specifications and resources visit the ARCHITECT Immunoassay Systems page.

 

 

 

SARS-CoV-2-IGM_Alinity-cartridge-Trans.png

For more information contact your Abbott Representative.

 

    

COMPREHENSIVE TESTING SOLUTIONS

 

Abbott’s intention is to offer as many solutions as possible across our diagnostics platforms to help test millions of people around the world. 


Explore


Infectious Disease Icon.png Infectious Disease Assays 

Our extensive assay menu helps physicians make timely, informed decisions throughout the continuum of care. 

Explore Infectious Disease  

portal_image_300x200.jpg Customer Portal

Receive exclusive benefits and resources with access to the Abbott Customer Portal.

Register now 

patient-clinician_300x200.jpg
COVID-19 Tools for Clinicians

Visit Abbott's latest COVID-19 Clinician tools that help develop insights and manage patient care. 

Access the tools

 

References
  1. Rogers TF, Zhao F, Huang D, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 2020;369(6506):956-963.
  2. Krammer, F. SARS-CoV-2 vaccines in development. Nature 2020;586(7380):516-527.
  3. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA Published online March 27, 2020. doi:10.1001/jama.2020.4783.
  4. Grzelak L, et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med 2020:12(559).
  5. DomBourian, et al. Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays. J Immunol Methods Accepted manuscript. Published online 20 August 2020.
  6. Abbott ARCHITECT SARS-CoV-2 IgG II Quant Reagent Instructions for Use. April 2021.
  7. Abbott Alinity i SARS-CoV-2 IgG II Quant Reagent Instructions for Use. April 2021.
  8. Zhao J, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Inf Dis Accepted Manuscript. Published online March 28, 2020. doi:10.1093/cid/ciaa344.
  9. Abbott ARCHITECT SARS-CoV-2 IgM Instructions for Use. May 2021.
  10. Abbott Alinity i SARS-CoV-2 IgM Instructions for Use. May 2021.
  11. World Health Organization. Laboratory testing strategy recommendations for COVID-19: interim guidance, March 21, 2020. World Health Organization; 2020.
  12. Abbott ARCHITECT SARS-CoV-2 IgG Instructions for Use. June 2020.
  13. Abbott Alinity i SARS-CoV-2 IgG Instructions for Use. June 2020.

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

DO YOU WISH TO CONTINUE AND EXIT THE CORE LABORATORY WEBSITE?

Content is not under the control of corelaboratory.abbott.

Yes No